health $wellness blog

Faridkot: Baba Farid University of Health Sciences (BFUHS) has announced the schedule of the stray vacancy round for NEET UG (MBBS, BDS) courses.  The last date for fresh online registration/application and deposition of application and security deposit for fresh applicants along with the fee of Rs. 5000+18%GST (Rs. 5900/-) and Rs. 2500+18%GST (Rs. 2950/- for SC candidates) through the university payment portal is 26.09.2023 (up to 03:00 PM). Fresh registered candidates will have to submit willingness along with a security deposit for the stray vacancy round. The last date for submitting willingness along with a security deposit by all the candidates (already registered candidates and fresh applicants) is 26.09.2023 (up to 05:00 PM). The amount of security to be deposited for submitting willingness will be as under – 1. For Government colleges - Rs. 10000/- (half for SC/BC) 2. For both Govt. & Private Colleges – Rs. 100000/ 3. For Private Colleges – Rs. 100000/- The las...

A two-year phase II TULIP-LN trial (NCT02547922) demonstrated the safety and efficacy of anifrolumab in treating active lupus nephritis, with the intensified dosing regimen showing particularly encouraging results. The findings were published in Lupus Science & Medicine. The trial enrolled 147 patients who were randomly assigned to receive one of two anifrolumab dosing regimens or a placebo. Patients in the intensified regimen (IR) group received intravenous anifrolumab 900 mg for the first three doses, followed by 300 mg of anifrolumab every four weeks. The basic regimen (BR) group received 300 mg of anifrolumab, and the placebo group followed a similar dosing schedule. To continue into Year 2 of the trial, patients had to achieve at least a partial renal response and meet a glucocorticoid tapering target. Out of the 101 patients who completed Year 1 of the study, 75 continued into Year 2, with 29 in the anifrolumab IR group, 23 in the BR group, and 23 in the placebo group. Dur...

Telangana: Kaloji Narayana Rao University of Health Sciences (KNRUHS) has begun the registration process for NEET MDS courses under management and competent quota after the reduction of the cut-off percentile. Candidates can register online and upload scanned certificates on the website https://tsmds.tsche.in  till 27-09-2023 up to 5:00 PM for both the above quotas. In accordance with Letter No. U12021/07/2023-MEC(Pt.1) Dated: 20.09.2023 from Ministry of Health and Family Welfare Government of India, online registrations are accepted from NEET-MDS-2023 qualified candidates after reduction of NEET-MDS cut-off score, who have not registered in response to the earlier notifications issued for online registration for admission under management and competent quota into Dental Colleges affiliated to KNR University of Health Sciences including Army Dental College in the State of Telangana. Also Read: MBBS Admissions: KNRUHS Issues Notice on Free Exit Of Admitted Candidates Under Mana...

Stem cells harvested from a person’s own bone marrow or blood, can safely slow progression of the most common form of the autoimmune disease, multiple sclerosis, or MS as it’s usually known, finds research published online in the Journal of Neurology Neurosurgery & Psychiatry. Autologous haematopoietic stem cell transplantation, or aHSCT for short, is usually used to treat blood cancers, and involves harvesting stem cells from the person’s own bone marrow or blood followed by chemotherapy and antibody treatment. Emerging evidence indicates that it is suitable for treating relapsing-remitting MS-characterised by distinct inflammatory episodes that cause varying degrees of residual disability. But aHSCT has yet to be included in most national clinical guidelines. The researchers therefore wanted to assess its safety and effectiveness when used in routine healthcare rather than under clinical trial conditions. They identified 231 patients with relapsing-remitting MS, 174 of whom ...

Guwahati: The NRI quota for MBBS courses in Assam's government medical colleges is poised for discontinuation starting the next academic year. The decision follows the admission of 23 NRI-sponsored candidates in the current academic year. Sources from the State Directorate of Medical Education (DME) have informed India Today NE that, in accordance with a recent Supreme Court verdict, there will be no provision for NRI quota seats in the state's medical colleges in the forthcoming academic year. Initially designated for economically weaker sections (EWS), a set of seats in Assam's medical colleges saw a transformation, now being allocated to the NRI quota. This alteration led to the enrollment of 23 NRI-sponsored candidates in the current academic year. This shift was permitted as the admission process had already progressed significantly and did not contravene the Supreme Court's directives. Also Read: Silchar Medical College Hospital Intern doctor suspended for a...

Dr Christopher R. King and colleagues at Washington University School of Medicine, USA have found i n a recent single-center pilot randomized clinical trial that  support from an intraoperative telemedicine center augmented by real-time clinical decision support did not affect intraoperative quality of care measures. The clinical trial called ACTFAST-3 (Anesthesiology Control Tower–Feedback Alerts to Supplement Treatments) was  aimed to implement real-time intraoperative telemedicine decision support and assess its impact on various aspects of surgical care. The study, conducted over several years, involved a substantial number of adult surgical patients and aimed to improve the quality of intraoperative care. The study has been published in JAMA Network Open.  The objective was to implement real-time intraoperative telemedicine decision support and evaluate its impact on postoperative hypothermia, hyperglycemia, and other quality of care measures. Study Period:...

Abbott Park , Ill.:  Abbott has announced an agreement with Spain-based mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women's health and respiratory diseases in emerging markets. The first molecules are expected to launch in 2025, while others are subject to the completion of clinical development and registration. Abbott will register and commercialize the biosimilars in key emerging countries in Latin America, Southeast Asia, the Middle East and Africa, leveraging the company's broad in-country footprint to make these cutting-edge medicines available to more people in emerging countries. mAbxience, with majority ownership from Fresenius Kabi and partial ownership from Insud Pharma, will manufacture the biosimilars in one of its two state-of-the art and Good Manufacturing Practices (GMP)-approved facilities in Spain and Argentina. Additionally, mAbxience will be responsible for achieving the clinical milestones for some of the molecules ...